Home / Press Releases

Press Releases

Radient Technologies Inc. Receives TSXV Approval to Extend Warrants

EDMONTON, Alberta, April 02, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces that it has received the approval from  the TSX Venture Exchange (the “TSXV”) to extend the term of 1,070,712 warrants originally scheduled to expire on April 14, 2020 (the “Warrants”) to April 14, 2021.

The Warrants were originally issued pursuant to a private placement of units completed by the Company on October 14 , 2016.  The new expiry date for these warrants is April 14, 2021.

All other terms and conditions of the warrants remain unchanged.  The Company’s intention to seek extension of these warrants was previously announced on March 31, 2020.

About Radient
Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.

SOURCE: Radient Technologies Inc.

Contact: Adam Deffett, Sr. VP Corporate Development: adeffett@radientinc.com

Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the extension of the term of the Warrants and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Amarex, an NSF International Company, Executes Five Rush COVID-19 Related Submissions to the FDA

The submissions include an IND, IND Amendment and Compassionate Use Approval for CytoDyn’s product Leronlimab, a Compassionate Use Approval for a treatment device, and an Emergency Use Authorization for a PCR-based IVD for COIVD-19 detection

Ann Arbor, Mich., USA, April 02, 2020 (GLOBE NEWSWIRE) — In early March 2020, Amarex Clinical Research LLC, an NSF International company, executed a rush submission of an emergency use Investigational New Drug (IND) application to add COVID-19 as a new indication for CytoDyn’s monoclonal antibody product, Leronlimab. The product is currently being tested for HIV infection, and oncology indications, and has the potential to modulate the “cytokine storm” sometimes seen in COVID-19 patients. A “cytokine storm” is an overproduction of immune cells and their activating compounds, which can contribute to life-threatening respiratory distress.

CytoDyn received rapid approval from the FDA for the emergency treatment of extremely ill COVID-19 patients. On March 27, CytoDyn released initial positive results in the first four patients treated, having seen a reduction of the hyper-immune response three days following treatment initiation. As of April 1, CytoDyn reported that a total of 10 patients have received treatment under emergency use. On March 30, FDA cleared a second IND for a Phase II randomized trial to treat mildly to moderately ill coronavirus patients with Leronlimab, with enrollment to begin immediately. Amarex is currently managing the trial. On April 1, CytoDyn reported that it filed an IND amendment with the FDA for a protocol to treat severely ill COVID-19 patients with Leronlimab where the primary endpoint is mortality rate at two weeks. Amarex also prepared this submission.

On March 25, Amarex also executed a rush submission to the U.S. FDA for a Compassionate Use Approval (CUA) for treatment of COVID-19 patients with a device that is currently in testing under an existing Investigational Device Exemption (IDE) for a different medical condition. Based on the mechanism of action there is reason to believe that the device may be an effective treatment for COVID-19 patients displaying serious symptoms. Amarex prepared the submission in a matter of days, which included writing a new clinical trial protocol; the typical submission process can take five weeks or more.

On March 27, Amarex executed a rush submission to the U. S. FDA of an Emergency Use Authorization (EUA) for a PCR-based IVD for the rapid detection of the coronavirus (SARS-CoV-2). The FDA quickly acknowledged receipt of the EUA and Amarex awaits a decision. The IVD has been through the regulatory approval process in Korea, and Amarex and its client are therefore hopeful for a rapid FDA approval result.

“I count myself lucky to work with our Amarex team,” said Amarex President and CEO Dr. Kazem Kazempour. “They’re incredibly caring, dedicated people as well as skilled experts who have been quick to adapt to this rapidly-changing situation.”

About Amarex Clinical Research LLC, an NSF International Company

Since 1998, Amarex has been helping biotech, pharmaceutical, medical device and diagnostic companies conduct scientifically sound clinical trials and navigate complex regulatory environments in a wide range of therapeutic indications, including oncology, central nervous system, wound healing, infectious disease, cardiovascular and urology.

As part of NSF International, Amarex supports companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.

About NSF International

NSF International has been protecting and improving human health for over 75 years. As a global public health organization NSF facilitates standards development, and tests and certifies products for the food, water, health sciences and consumer goods sectors to minimize adverse health effects. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF International is a Pan American Health Organization/World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Indoor Environment.

NSF’s health sciences services include training and education, consulting, clinical research, regulatory guidance, corporate compliance and, separately, auditing, DNA testing, certification and R&D for the pharma biotech, medical device and dietary supplement industries throughout the product lifecycle. NSF facilitated the development of the only American National Standard (NSF/ANSI 173) that verifies the health and safety of dietary supplements and also tests and certifies products to this standard.

About CytoDyn, Inc.

CytoDyn Inc. is a biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for Leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with Leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of Leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that Leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that Leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on Leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate Leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with Leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.

Please direct media inquiries to Ken Bearden at media@nsf.org or +1.734.769.5167.

Kenneth Bearden
NSF International
+1 734 769 5176
kbearden@nsf.org

ALIGN TECHNOLOGY COMPLETES ACQUISITION OF EXOCAD, A GLOBAL DENTAL CAD/CAM SOFTWARE LEADER

SAN JOSE, Calif. and DARMSTADT, Germany, April 02, 2020 (GLOBE NEWSWIRE) — Align Technology, Inc. (Align) (Nasdaq: ALGN) today announced that it has completed the acquisition of privately-held exocad Global Holdings GmbH (exocad), a global leader in the dental CAD/CAM software market that offers fully integrated workflows to dental labs and dental practices via a broad customer base of partners and resellers in over 150 countries.

The acquisition of exocad broadens Align’s digital platform reach by adding technology that addresses restorative needs in an end-to-end digital platform workflow to facilitate ortho-restorative and comprehensive dentistry. The acquisition brings exocad’s expertise in restorative dentistry, implantology, guided surgery, and smile design to the Align technology portfolio. It extends Align’s Invisalign and iTero digital solutions, paving the way for new, seamless cross-disciplinary dentistry in the lab and at chairside. exocad also broadens Align’s platform reach in the digital dentistry with close to 200 partners and more than 35,000 licenses installed worldwide.

Commenting on today’s announcement, Joe Hogan, Align Technology president and CEO said, “The acquisition of exocad is a natural next step in the collaboration between our two companies that began in 2017. Now, we are excited for the next phase in our journey to continue driving the evolution of digital dentistry. exocad’s visionary founders, Till Steinbrecher and Maik Gerth, and their experienced software team, will enhance our technology capabilities and enable future digital innovation. Together, we will extend exocad’s position as a key technology provider for the dental CAD/CAM industry and drive continuous innovation with the open and integrated approach that is the foundation of the company.”

exocad will continue to operate as it exists today, enabling it to support a broad ecosystem of partners and end-users and continue to deliver hardware-independent software solutions. exocad co-founders Tillmann Steinbrecher and Maik Gerth, along with their team, will remain with the Company and report into John Morici, Align Technology, senior vice president and CFO. Align plans to maintain all exocad products and services.

About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, and iTero® intraoral scanners and services. Align’s products help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com.

About exocad GmbH
exocad GmbH is a dynamic and innovative software company committed to expanding the possibilities of digital dentistry and providing OEMs (Original Equipment Manufacturers) with flexible, reliable, and easy-to-use CAD/CAM software for dental labs and dental practices. exocad software has been chosen by leading OEMs worldwide for integration into their dental CAD/CAM offerings, and thousands of exocad DentalCAD licenses are sold each year. For more information and a list of exocad reseller partners, please visit www.exocad.com.

Align Technology Zeno Group
Madelyn Homick Sarah Johnson
(408) 470-1180 (828) 551-4201
mhomick@aligntech.com sarah.johnson@zenogroup.com

Forward-Looking Statements
This news release, including the tables below and other information publicly disseminated by us, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including quotations from management, and statements regarding (i) expected transaction benefits and synergies as a result of the acquisition, (ii) future development efforts and the potential for digital innovation market positioning, (iii) product and service offerings, and (iv) operational and personnel expectations, in addition to other matters discussed in this press release that are not purely historical data. We do not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement.

Among the factors that could cause actual results to differ materially from those contemplated include, without limitation:

  • the impact of the COVID-19 pandemic on the the health and safety of our employees, customers, patients, and our suppliers as well as the physical and economic impacts of the various recommendations, orders and protocols issued by local and national governmental agencies in light of the evolving situation
  • the ability to: (i) realize expected synergies or benefits in connection with the transaction within the expected timeframes or not at all and (ii) timely, cost-efficiently and effectively integrate exocad’s business without adversely impacting operations of either Align or exocad;
  • the effect of the closing of the transaction on (i) Align’s and exocad’s relationships with their respective customers, suppliers, strategic partners and competitors and their operating results and businesses generally (including the diversion of management time on transaction-related issues) and (ii) the ability to retain and hire key personnel;
  • uncertainties associated with any aspect of the transaction, including those related to (i) fluctuations in foreign exchange rates and transaction costs, and (ii) litigation in connection with the transaction itself or ongoing matters acquired from exocad;
  • the potential that our due diligence did not uncover risks and potential liabilities associated with the exocad acquisition;
  • risks relating to financial reporting including those resulting from the implementation of new or changed accounting policies and practices as well as associated system implementation in the context of the transaction as well as our ability to forecast financial results;
  • the potential impact of the transaction on our future tax rate and payments based on the consolidation of the global group and our ability to integrate foreign operations;
  • the potential negative effects of the closing of the transaction on the market price of Align’s common stock;
  • difficulties predicting customer and consumer purchasing behavior;
  • expectations regarding the continued growth of our international markets;
  • increasing competition from existing and new competitors;
  • rapidly evolving and groundbreaking advances that are fundamentally changing the dental industry and the way new and existing participants market and provide products and services to consumers;
  • our ability to protect our intellectual property rights;
  • our expectations regarding sales growth of our intra-oral scanner sales in international markets and our belief that technology features and functionality of our iTero scanners and exocad products will increase adoption of Invisalign and increase sales of our intra-oral scanners;
  • the possibility that the development and release of new products or enhancements to existing products do not proceed in accordance with the anticipated timeline or may themselves contain bugs or errors requiring remediation and that the market for the sale of these new or enhanced products may not develop as expected, or that the expected benefits of new or existing business relationships will not be achieved as anticipated;
  • the compromise of employee, customer and/or patient data for any reason;
  • changes in consumer spending habits as a result of, among other things, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence; and
  • foreign operational, political and other risks relating to our international manufacturing operations.

The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (SEC) on February 28, 2020. Securities and Exchange Commission filings can be accessed over the Internet at http://www.sec.gov/edgar/searchedgar/companysearch.html. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

AirBoss Defense Group Selected by FEMA to Support the US National COVID-19 Response

Delivering Powered Air Purifying Respirators and High Efficiency Filters to Federal Government

The ADG FlexAir™ PAPR System

The FlexAir™ PAPR System is a compact, lightweight respirator system powered by an onboard battery in a waist-mounted blower, designed and manufactured in the United States.

LANDOVER, Md., April 01, 2020 (GLOBE NEWSWIRE) — AirBoss Defense Group (ADG) announced today that the U.S. Government has placed an initial order for 100,000 American-made FlexAir™ Powered Air Purifying Respirators (PAPR) and 600,000 High Efficiency Filters for urgent response to the COVID-19 pandemic. The FlexAir™ PAPR is designed to enable medical providers and first responders unencumbered protection over extended periods of time while providing critical medical care.  The value of the contract is expected to be $96.4M and deliveries will begin immediately and are expected to be completed over the next 13 weeks.

The FlexAir™ PAPR System is a compact, lightweight respirator system powered by an onboard battery in a waist-mounted blower, designed and manufactured in the United States.  The flexible design permits the use of 2 High Efficiency particulate filters, providing a high level of protection against biological viruses like COVID-19.

“This is war, and President Trump is using the full force of the federal government and the full power of private enterprises like ADG to rapidly mobilize our industrial base to fight the hidden enemy of COVID-19,” said Dr. Peter Navarro, White House Director of the Office of Trade and Manufacturing Policy.  “ADG has stepped up with lightning speed, and their willingness to help meet the urgent need for powered respirators will save American lives. This crisis has shown that maintaining and supporting a strong U.S. manufacturing base is of critical importance to our nation’s economic security and national defense.”

Patrick Callahan, CEO of AirBoss Defense Group said, “ADG is honored to apply our engineering and manufacturing capabilities towards protecting the lives of front-line medical professionals and first responders.  FlexAir™ PAPR systems are designed to provide caregivers ultimate protection against biological threats, including COVID-19, enhancing the life-saving capabilities of our dedicated health care workers.  The entire company is completely focused on delivering these products on an accelerated timeline, to Federal, state and local authorities as well directly to frontline health care professionals. As our products are manufactured in the United States, we are prepared to quickly provide lifesaving products as the need for protective equipment evolves.”

ADG is an umbrella survivability group that provides military, law enforcement, medical providers, industrial providers and first responders with a diverse portfolio of protective equipment that spans the entire survivability spectrum. AirBoss Defense, an ADG brand, is a recognized world leader in rapid deployment negative pressure isolation shelters, medical protection equipment, and personal respiratory protective products. AirBoss Defense’s emergency response and protective equipment is utilized by the U.S. Department of State, Office of Strategic Medical Preparedness, FEMA and CDC infectious disease treatment centers.

In addition, AirBoss Defense provides protective equipment to emergency medical response teams and hospitals in over 1,500 U.S. cities, as well as over 30 countries worldwide. The company successfully responded during the MERS and Ebola outbreaks, by providing critical protective equipment to government and civilian medical customers.  The company will continue to engage in the response to the COVID-19 outbreak through the rapid delivery of domestically manufactured personal protection equipment and patient isolation systems to the medical community.

For more information, please visit www.adg.com.

FORWARD LOOKING INFORMATION DISCLAIMER

Certain statements contained or incorporated by reference herein, including those that express management’s expectations or estimates of future developments or ADG’s future performance, constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws, and can generally be identified by words such as “will”, “may”, “could” “is expected to”, “believes”, “anticipates”, “forecasts”, “plans”, “intends” or similar expressions.  These statements are not historical facts but instead represent management’s expectations, estimates and projections regarding future events and performance.

Statements containing forward-looking information are necessarily based upon a number of opinions, estimates and assumptions that, while considered reasonable by management at the time the statements are made, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies.  ADG cautions that such forward-looking information involves known and unknown contingencies, uncertainties and other risks that may cause ADG’s actual financial results, performance or achievements to be materially different from its estimated future results, performance or achievements expressed or implied by the forward-looking information.  Numerous factors could cause actual results to differ materially from those in the forward-looking information, including without limitation: impact of general economic conditions; dependence on key customers; sufficient availability of raw materials at economical costs; weather conditions affecting raw materials, production and sales; ADG’s ability to maintain existing customers or develop new customers in light of increased competition; ADG’s ability to successfully integrate acquisitions of other businesses and/or companies or to realize on the anticipated benefits thereof, changes in accounting policies and methods, including uncertainties associated with critical accounting assumptions and estimates; changes in tax laws and potential litigation; ability to obtain financing on acceptable terms; environmental damage and non-compliance with environmental laws and regulations; potential product liability and warranty claims and equipment malfunction.  This list is not exhaustive of the factors that may affect any of ADG’s forward-looking information.

All of the forward-looking information in this press release is expressly qualified by these cautionary statements.  Investors are cautioned not to put undue reliance on forward-looking information.  All subsequent written and oral forward-looking information attributable to ADG or persons acting on its behalf are expressly qualified in their entirety by this notice.  Forward-looking information contained herein is made as of the date of this press release and, whether as a result of new information, future events or otherwise, ADG disclaims any intent or obligation to update publicly this forward-looking information except as required by applicable laws.  Risks and uncertainties about ADG’ business are more fully discussed under the heading “Risk Factors” in AirBoss of America Corp.’s (“AirBoss”) recent Annual Information Form and are otherwise disclosed in AirBoss’ filings with securities regulatory authorities which are available on SEDAR at www.sedar.com.

AirBoss Defense Group
3341 75th Avenue, Suite GG
Landover, Maryland
Contact: David Costello
Tel: 617.875.2492
Email: david@risingtidemhd.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c77ab8f1-fb3f-4fba-b8a0-0af5c8207413

iTeos Therapeutics Closes $125 Million Series B2 Financing

iTeos Therapeutics Closes $125 Million Series B2 Financing
 
– Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint –

– Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital –

– New investors Janus Henderson Investors, RTW Investments and Invus also participated along with previous Series B investors including MPM Capital and HBM Partners –
 
Cambridge, MA and Gosselies, Belgium – April 1, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today the closing of an oversubscribed Series B2 financing, which raised a total of $125 million.

The Series B2 financing round was co-led by RA Capital Management and Boxer Capital, and included new investors Janus Henderson Investors, RTW Investments and Invus along with existing investors MPM Capital, HBM Partners, 6 Dimensions Capital, Curative Ventures, Fund+, VIVES Louvain Technology Fund, SRIW, and SFPI.

Proceeds from the financing will support the Company’s continued growth and advance the clinical development of its two lead product candidates, EOS-850, a best-in-class adenosine A2A receptor antagonist and EOS-448, an ADCC-enabled anti-TIGIT antibody. EOS-850 is currently being evaluated in a Phase 1/2 clinical trial both as a single agent and in combination in several solid tumor indications. The Company plans to initiate dosing for the combination cohorts for this trial in the second quarter of 2020. The Company also recently initiated the Phase 1 portion of a Phase 1/2 clinical study of EOS-448, currently being evaluated in patients with solid tumors and hematological malignancies. Proceeds from this financing will also support the advancement of additional first-in-class preclinical programs targeting the adenosine pathway and Tregs.

“We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos,” said Michel Detheux, PhD, President and Chief Executive Officer at iTeos. “We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership.”

“iTeos’ pipeline of best-in-class agents has the potential to usher in a new wave of immuno-oncology therapeutics and the Company is well-positioned to make a significant, positive impact in the treatment of patients with a wide variety of cancer types,” commented Derek DiRocco, Principal, RA Capital Management. “We are thrilled to collaborate with this experienced group of high-quality investors and partner with the iTeos management team as they continue to innovate and progress these exciting programs through clinical development.”

“The iTeos team has done a remarkable job developing a pipeline of differentiated, potentially best-in-class cancer therapies,” said Aaron Davis, Co-Founder and Chief Executive Officer, Boxer Capital of the Tavistock Group.  “We are pleased to be joining them as they continue to execute and implement their vision for transforming the cancer treatment landscape.”

Derek DiRocco and Aaron Davis will join the iTeos Board as Non-Executive Directors.

About iTeos Therapeutics
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com.

About RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit https://www.racap.com.

About Boxer Capital, LLC
Boxer Capital, LLC is a private biotechnology investment fund based in San Diego, California that invents and invests in drug development across multiple therapeutic indications.  Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital maintains a concentrated portfolio of public and private companies.  For more information, please visit www.boxercap.com.

For further information, please contact:
Michel Detheux, CEO
iTeos Therapeutics SA
info@iteostherapeutics.com

Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com

Sarah McCabe and Zofia Mita
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com

Philips enables hospitals and GPs to remotely screen and monitor patients with COVID-19

April 1, 2020

  • Philips provides healthcare institutions with telehealth solution to process high volume coronavirus-related healthcare requests via online screening, and supports healthcare providers in the use of external call centers to offer the correct care to patients
  • If medically justified, patients infected with COVID-19 can be remotely monitored via automated questionnaires about their home situation and state of health

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it can help general practitioners and healthcare institutions manage the increased patient flows resulting from the COVID-19 outbreak through a dedicated and scalable telehealth solution that facilitates the use of online screening, follow-up questionnaires and monitoring, and external call center collaborations. It aims to prevent unnecessary visits to general practitioners and hospitals and the remote monitoring of the vast majority of COVID-19 patients that are in quarantine at home.

As a first step, patients complete an online questionnaire at home. Based on the results, the caregiver can let the online solution assign patients to a risk class and take appropriate actions. If needed patients can be monitored via automated follow-up surveys. Patients with a high-risk score are called by a call center for additional information. If the call center determines that care is required, the patient is referred to the GP, who can then provide the necessary care or send them to the hospital. While the questionnaire is intended to support care providers, it is explicitly not a substitute for regular or emergency care. The solution is based on Philips’ existing and proven Patient Reported Outcomes Management solution, which is being used by more than 100 healthcare institutions globally.

The Groene Hart Hospital in Gouda, the Netherlands, is one of the healthcare institutions that has not only already started using the COVID-19 screening and monitoring solution but has also contributed to its development. “We are using this application to relieve the enormous pressure currently placed on our healthcare system,” said Ronald Liem, Head of Surgery at the Groene Hart Hospital. “Together with general practitioners and the Dutch public health service, we can now focus on the most urgent cases and determine, based on the answers from the surveys, which patients do and which do not need additional care.”

“The outbreak of the new coronavirus is a major challenge for everyone in healthcare,” said Roy Jakobs, Chief Business Leader Connected Care, member of the Executive Committee, Royal Philips. “That is why we have equipped one of our existing and proven telehealth solutions with the capabilities to screen and monitor patients remotely. This remote screening solution supports healthcare institutes to diagnose and treat patients at alternative points of care and is helping to safeguard the scarce critical care capacity.”

Roy Jakobs added: “We have a broad portfolio of telehealth and remote care solutions at Philips. We are now working with hospitals and GPs to see how we can use these solutions to help frontline healthcare workers and their patients during the COVID-19 crisis.”

Hospitals, general practitioners and other care providers who want to know more about Philips’ screening and monitoring solution for COVID-19 patients can visit our website.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

33rd Electric Vehicle Symposium and Exposition scheduled for June 14-17 in Portland, Oregon

WASHINGTON, March 31, 2020 (GLOBE NEWSWIRE) — Siemens AG CEO Joe Kaeser and other key speakers, sponsors and exhibitors from the entire electric drive supply chain, including R&D experts, leading manufacturers, top industry executives and government partners, are slated to participate in the 33rd Electric Vehicle Symposium and Exposition (EVS33), scheduled for June 14 thru 17, 2020, in Portland, Oregon, USA.

“Electric drive technologies are advancing rapidly, and transportation electrification is expanding around the globe,” said Genevieve Cullen, president of the Electric Drive Transportation Association (EDTA), the US association dedicated to advancing electric drive technologies and organizer of the symposium. Cullen continued, “EDTA, our partner organizations within the World Electric Vehicle Association (WEVA) and co-host Forth are working to build on these successes, grow opportunity and increase the number of people, localities, states, regions, and countries that benefit from electric transportation. EVS33 participants can be part of that progress.”

With a history spanning five decades, the EV Symposium & Exposition has become the premier forum for sharing research, best practices, technology breakthroughs and engaging with other industry stakeholders. EVS33 features include plenary sessions, lectures and dialogue sessions led by industry leaders, technology experts and government partners. The event will cover essential and pressing topics in electric drive and encompass a focus on vehicles, infrastructure, vehicle systems and applications, public policy, market development and deployment case studies.

In addition to the dynamic speaker and presentation lineup, EVS33 plans include an exhibition hall to feature the latest technologies from global companies representing every segment of the industry and a Ride, Drive & Charge with the latest electric cars, scooters, bikes and charging equipment. A public day scheduled for June 14 will give local residents a chance to experience the Ride, Drive & Charge and exhibition hall.

EVS33 organizers remain committed to the health and safety of event participants and are closely monitoring the circumstances surrounding the novel coronavirus (COVID-19), following guidance from the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and recommendations set forth by the United States, Oregon and local Portland governments. Currently, the EVS33 event falls outside the mandated restrictions, and work to deliver a premier international electric vehicle symposium continues. EVS33 organizers will provide regular updates and make informed decisions that follow guidance and recommendations that safeguard the health of participants. Updates are posted on the EVS33 website at www.EVS33Portland.org.

About EDTA: The Electric Drive Transportation Association (EDTA) is the trade association representing battery, hybrid, plug-in hybrid and fuel cell electric drive technologies and infrastructure. EDTA conducts public policy advocacy, education, industry networking, and international conferences, including EVS33. EDTA’s membership includes vehicle and equipment manufacturers, utilities, technology developers, component suppliers and others. For more information about EDTA and its members, visit ElectricDrive.org. For information about owning and operating electric vehicles, please visit GoElectricDrive.org.

Contact:
Christine Spann
Electric Drive Transportation Association
cspann@electricdrive.org